TABLE 3.
Participant | ACS visit no. | Time (mo) | Result by: |
|||
---|---|---|---|---|---|---|
Original MT-2 assay | Repeat MT-2 assay | Original Trofile assay | Enhanced-sensitivity Trofile assay | |||
13993 | 35 | 0 | − | + | R5 | R5 |
36 | 3 | − | + | R5 | R5 | |
37 | 6 | + | + | R5 | D/M | |
38 | 9 | + | + | D/M | D/M | |
39 | 12 | − | + | D/M | D/M | |
40 | 15 | − | D/M | D/M | ||
41 | 18 | − | D/M | D/M | ||
42 | 21 | + | D/M | D/M | ||
43 | 34 | + | D/M | D/M | ||
13988 | 19 | 0 | − | − | R5 | R5 |
20 | 3 | − | − | R5 | R5 | |
21 | 6 | − | − | R5 | R5 | |
22 | 9 | + | − | R5 | R5 | |
23 | 12 | + | + | |||
24 | 15 | + | + | Fail | ||
25 | 18 | + | R5 | R5 | ||
26 | 20 | + | D/M | D/M | ||
27 | 23 | + | D/M | D/M | ||
28 | 27 | + | R5 | R5 | ||
13951 | 20 | 0 | − | − | R5 | R5 |
21 | 3 | − | + | R5 | R5 | |
22 | 6 | + | + | R5 | D/M | |
23 | 9 | + | + | R5 | R5 | |
24 | 12 | + | + | D/M | D/M | |
25 | 15 | + | R5 | D/M | ||
27 | 19 | + | R5 | D/M | ||
13940 | 17 | 0 | − | − | R5 | D/M |
18 | 3 | − | + | R5 | D/M | |
19 | 5 | + | + | R5 | D/M | |
20 | 9 | + | + | R5 | D/M | |
21 | 12 | + | + | D/M | D/M | |
22 | 15 | + | R5 | D/M | ||
23 | 18 | + | D/M | D/M | ||
25 | 21 | + | D/M | D/M | ||
13912 | 10 | 0 | − | R5 | R5 | |
11 | 3 | − | Fail | |||
12 | 6 | + | D/M | D/M | ||
13 | 9 | + | D/M | D/M | ||
14 | 12 | + | R5 | R5 | ||
15 | 15 | + | D/M | |||
16 | 18 | + | D/M | |||
13908 | 8 | 0 | − | R5 | R5 | |
9 | 4 | − | D/M | D/M | ||
10 | 7 | + | D/M | D/M | ||
11 | 10 | + | D/M | D/M | ||
14 | 14 | + | D/M | D/M | ||
26 | 27 | + | D/M | D/M | ||
41 | 43 | + | D/M | D/M | ||
13907 | 7 | 0 | − | R5 | R5 | |
8 | 2 | − | R5 | R5 | ||
9 | 5 | + | D/M | D/M | ||
10 | 8 | + | D/M | D/M | ||
11 | 11 | + | D/M | D/M | ||
15 | 18 | + | D/M | D/M | ||
25 | 26 | + | D/M | D/M | ||
32 | 33 | + | D/M | D/M | ||
13904 | 19 | 0 | − | R5 | R5 | |
20 | 1 | − | R5 | R5 | ||
22 | 3 | + | R5 | D/M | ||
23 | 4 | + | R5 | R5 | ||
25 | 6 | + | D/M | D/M | ||
26 | 6 | + | D/M | D/M | ||
28 | 8 | Fail | D/M | D/M | ||
13885 | 9 | 0 | − | Fail | ||
10 | 3 | − | Fail | |||
11 | 6 | + | D/M | D/M | ||
12 | 9 | + | D/M | D/M | ||
13 | 12 | + | D/M | D/M | ||
16 | 21 | + | D/M | D/M | ||
29 | 39 | D/M | D/M | |||
13845 | 2 | 0 | − | R5 | D/M | |
3 | 3 | − | R5 | D/M | ||
4 | 6 | + | D/M | D/M | ||
5 | 9 | + | D/M | D/M | ||
6 | 12 | + | D/M | D/M | ||
7 | 15 | + | D/M | D/M | ||
9 | 21 | D/M | D/M |
Time, time from the first visit tested in this study; original MT-2 assay, results of the MT-2 assay performed with fresh patient PBMCs in real time; repeat MT-2 assay, results of the MT-2 assay performed with cryopreserved patient PBMCs from the same time points in 2006; −, negative MT-2 culture result; +, positive MT-2 culture result; R5, CCR5 using; Fail, assay failure; D/M, dual or mixed tropism.